SCHEMBL30775281

SCHEMBL30775281

CN(C)c1ccc(-c2ccncc2)c2c1C(=O)NC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.43
PARP11 Q9NR21 1/20 0.43
CSF1R P07333 2/20 0.42
CDC7 O00311 5/20 0.38
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37
KDR P35968 6/20 0.36
BRAF P15056 2/20 0.36
MAP3K9 P80192 1/20 0.35
MAP3K11 Q16584 1/20 0.35
PKN1 Q16512 1/20 0.35
PKN2 Q16513 1/20 0.35
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.33
PDE5A O76074 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
PTGS1 P23219 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18170546 0.78 KDR (0.50) PARP10PARP11CSF1RCDC7PDE3B
SCHEMBL29150545 0.78 CLK4 (0.42) PARP10PARP11CDC7PDE3BPDE3A
SCHEMBL30701043 0.78 KDR (0.50) PARP10PARP11CSF1RCDC7PDE3B
SCHEMBL30775227 0.78 PDE3B (0.45) PARP10PARP11CDC7PDE3BPDE3A
SCHEMBL30775326 0.77 CSF1R (0.47) PARP10PARP11CSF1RKDR
SCHEMBL22663482 0.75 CSF1R (0.42) PARP10PARP11CSF1RKDRMAP3K9
SCHEMBL18170438 0.73 CDC7 (0.40) PARP10PARP11CDC7KDRBRAF
SCHEMBL30775395 0.73 PARP10 (0.39) PARP10PARP11CDC7BRAFMAP3K9
SCHEMBL29845432 0.70 CLK4 (0.57) PARP10PARP11CSF1RCDC7KDR
SCHEMBL30775303 0.69 CSF1R (0.40) PARP10PARP11CSF1RCDC7PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR PARP10 2840/4885PARP11 2862/4885CSF1R 4106/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR PARP10 2840/4885PARP11 2862/4885CSF1R 4106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.